Get the Stockscreener App
5.2818
5.69%
0.2718
Achieve Life Sciences Inc stock is traded at $5.2818, with a volume of 654.59K.
It is up +5.69% in the last 24 hours and up +12.90% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$5.01
Open:
$5.02
24h Volume:
654.59K
Relative Volume:
0.41
Market Cap:
$541.01M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-4.0792
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
-1.21%
1M Performance:
+12.90%
6M Performance:
+18.72%
1Y Performance:
+38.98%
1-Day Range:
$4.91
$5.34
1-Week Range:
$4.82
$5.50
52-Week Range:
$2.00
$6.16
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
5.27 | 514.32M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
476.17 | 118.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.73 | 64.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
850.92 | 53.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.27 | 38.48B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
166.96 | 36.04B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Canaccord reiterates Achieve Life Sciences stock rating after CRL - Investing.com
Canaccord reiterates Achieve Life Sciences stock rating after CRL By Investing.com - Investing.com Australia
Wainwright reiterates Achieve Life Sciences stock rating after FDA letter - Investing.com
Achieve Life Sciences: CRL Is Fixable, So I Remain Bullish - Seeking Alpha
Achieve Life Sciences (ACHV) Receives FDA Complete Response Lett - GuruFocus
ACHV Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Achieve Life Sciences jumps despite cytisinicline CRL - MSN
Achieve Life Sciences (ACHV) Sees 10% Rise Despite FDA Complete Response Letter - GuruFocus
US FDA declines to approve Achieve Life Sciences' smoking-cessation drug - Reuters
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned - Benzinga
Achieve Life Sciences Shares Rise After Complete Response Letter From FDA - marketscreener.com
Achieve Life Sciences Receives FDA Complete Response Letter for Cytisinicline - marketscreener.com
Achieve Life Sciences receives FDA rejection on manufacturing issues - Investing.com
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA - The Manila Times
Achieve Life Sciences stock falls after FDA issues response letter By Investing.com - Investing.com South Africa
Achieve Life Sciences stock falls after FDA issues response letter - Investing.com
La FDA américaine refuse d'autoriser le médicament anti-tabagique d'Achieve Life Sciences - TradingView
Die US-amerikanische FDA lehnt die Zulassung des Medikaments zur Raucherentwöhnung von Achieve Life Sciences ab - TradingView
La FDA statunitense rifiuta di approvare il farmaco per smettere di fumare di Achieve Life Sciences - TradingView
Achieve Life FDA rejects cytisinicline filing over manufacturing issues - Stock Titan
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
Achieve Life Sciences, Inc.(NasdaqCM:ACHV) added to S&P Biotechnology Select Industry Index - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
FDA Readout Looms for ACHV, UNCY; Market Sees Split Odds - TechStock²
ACHV Slides On Heavy Selling As Traders Test Support - timothysykes.com
SpaceX, Microsoft, Netflix, Intel, and Achieve Life Sciences top retail buzz - scanx.trade
Achieve Life Sciences Inc (ACHV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Achieve Life Sciences Inc (ACHV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Achieve Life Sciences Inc (ACHV) Institutional Confidence - TradingKey
Achieve Life Sciences Inc (ACHV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Achieve Life Sciences Inc (ACHV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Achieve Life Sciences Inc (ACHV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Achieve Life Sciences Inc (ACHV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Achieve Life Sciences Inc (ACHV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lakeside Advisors, INC.'s Achieve Life Sciences Inc(ACHV) Holding History - GuruFocus
[ARS] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Achieve Life Sciences (NASDAQ: ACHV) plans vote to double share authorization - Stock Titan
ACHV Stock Chart | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences Adds Two Independent Board Directors - The Globe and Mail
Achieve Life Sciences (ACHV) director awarded 47,250 options at $5.24 strike - Stock Titan
Achieve Life (ACHV) director receives 47,250 options at $5.24 strike - Stock Titan
ACHIEVE Life Sciences (ACHV) director reports no beneficial ownership on Form 3 - Stock Titan
Achieve Life Sciences (ACHV) director Farrow files Form 3 with no share ownership - Stock Titan
Achieve Life Sciences, Inc. Announces Board Appointments - marketscreener.com
Achieve Life Sciences appoints two new directors to board and committees - Investing.com Nigeria
Achieve Life Sciences, Inc. Files Form 8-K Current Report with SEC on May 29, 2026 - Minichart
Achieve Life Sciences appoints two new directors to board and committees By Investing.com - Investing.com South Africa
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors - The Globe and Mail
[8-K] ACHIEVE LIFE SCIENCES, INC. Reports Material Event - Stock Titan
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences (ACHV) asks shareholders to double authorized common shares to 300M - Stock Titan
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
0.30%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):